The relationship between IL-10 and TNF-α gene polymorphism and therapy resistance to platelet transfusion and recombinant factor VII administration in Glanzmann Thrombasthenia

Background: Resistance to platelet and recombinant factor VII administration in patients with Glanzmann Thrombasthenia is a major problem causing bleeding, morbidity and mortality. There is no data on the risk factors for therapeutic resistance in Glanzmann Thrombasthenia. IL-10 and TNF-α play an important role in immune responses. Recent studies have shown that some of cytokine gene polymorphisms can produce different level of cytokines, altering severity of immune responses and therefore create therapeutic resistance. In this study, probably for the first time, the relationship between immune regulator genes in the development of resistance to therapy in Glanzmann Thrombasthenia patients is investigated.Method: this study was performed in Mashhad University of Medical Sciences in collaborative with Thalassemia and Hemophilia Center in Zahedan, Iran in 2017. Blood samples were collected from 15 therapy resistant Glanzmann Thrombasthenia patients and 15 therapy non-resistant patients as a control group. DNA was extracted and IL-10 and TNF-α gene polymorphism was analyzed by Taqman Realtime PCR Based Method. Results were analyzed by SPSS (V 11.5). Results: all patients in therapy resistant group had the IL-10 polymorphism at -1082 position (rs1800896) with G/G genotype that was significantly more frequent than the non- resistant group. However, we did not find any difference in the frequencies of TNF- polymorphisms between two groups. Conclusion: IL-10 gene polymorphism, was a risk factor for inhibitor formation and therapeutic resistance in Glanzmann Thrombasthenia patients. However, TNF- polymorphism was not associated with the development of therapeutic resistance in the patients.

کلیدواژه ها:

Glanzmann ، Thrombasthenia ، therapy resistance ، recombinant factor VII ، IL-10 ، TNF-